NUEVOLUTION A/S: Financial statements 2017
CVR: 26029708
Source: annual report 2017, Danish Business Authority
01/07/2016 – 30/06/2017
NUEVOLUTION A/S (CVR 26029708) has filed annual accounts for 2017. In 2017, the company reported revenue of DKK 91,853,000 and a net result of DKK -16,535,000 compared with DKK -104,854,000 the year before. That is an increase of 439.8% compared with the year before. The profit margin was -18%. Equity in the 2017 report amounted to DKK 61,395,000. The solvency ratio was 72.4%.
- Revenue
- DKK 91,853,000
- Profit/Loss
- DKK -16,535,000
- Equity
- DKK 61,395,000
- Total Assets
- DKK 84,781,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 91.9 mio. | - | -16.5 mio. | 61.4 mio. | - |
| 2016 | 17 mio. | -37.4 mio. | -104.9 mio. | 15.6 mio. | - |
| 2015 | 23.9 mio. | -22.5 mio. | -43.9 mio. | 41.7 mio. | - |
Keep an eye on NUEVOLUTION A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout NUEVOLUTION A/S
NUEVOLUTION A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CHEMGENE ApS. The management consists of Thomas Franch. The company is owned by Amgen, Inc.. The company has 59 employees (2018). In 2025, the company reported revenue of DKK 203,323,000 and a net result of DKK 39,754,000 compared with DKK -18,383,000 the year before. Equity in the 2025 report amounted to DKK 89,493,000.